Previous 10 | Next 10 |
TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system...
Palm Beach, FL – September 21, 2021 – FinancialNewsMedia.com News Commentary Growing prevalence of cardiovascular disorders (CVDs) globally is anticipated to substantially increase in the upcoming years. Hypertension, smoking, alcohol consumption, and consumption o...
InspireMD develops and commercializes proprietary stent designs with a proprietary mesh. The Company seeks to change the SoC in the treatment of CAD and other invasive indications utilizing an integrated embolic protection stent platform. The Company’s commercialized produc...
Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Ther...
Start Time: 8:30 End Time: 08:51 InspireMD, Inc. (NSPR) Q2 2021 Earnings Conference Call August 10, 2021, 08:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Jules Abraham - CORE IR Conference Call Participants Benjamin Haynor - Alliance Global Partners Presentation Operat...
The following slide deck was published by InspireMD, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: InspireMD, Inc. 2021 Q2 - Results - Earnings Call Presentation
Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET TEL AVIV, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prev...
TEL AVIV, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report fiscal first quarter 2021 ...
TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successf...
Gainers: ImmunoPrecise Antibodies (IPA) +157%.India Globalization Capital (IGC) +74%.NRx Pharmaceuticals (NRXP) +56%.Universe Pharmaceuticals (UPC) +30%.Summit Wireless Technologies (WISA) +28%.Support.com (SPRT) +25%.Agrify Corporation (AGFY) +20%.PainReform (PRFX) +19%.Resources Connec...
News, Short Squeeze, Breakout and More Instantly...
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prev...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...